Overview

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, dose escalation study of ARQ 197 in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)